Identifying Biomarker Candidates in the Blood Plasma or Serum Proteome
- 29 March 2017
- book chapter
- Published by Springer Nature
- Vol. 974, 193-203
Abstract
Brain disorders are among the most complex and difficult to understand of human disorders in terms of pathophysiology and etiology. Differently from other human diseases such as cancer, which uses biomarkers in clinical practice, there are no prognostic and diagnostic biomarkers available for psychiatric disorders. Those associated with the likelihood of a successful medication are also not existent, impairing treatment strategies. Proteomics is a suitable tool for identifying such biomarkers to be validated and further implemented in the clinic. Here we present a protocol for the proteome analyses of blood plasma and serum collected in vivo, aiming for the discovery of potential biomarkers and the comprehension of the molecular bases of diseases and treatments.Keywords
This publication has 17 references indexed in Scilit:
- Biomarkers for Psychiatric Disorders: Where Are We Standing?Disease Markers, 2013
- Improving Qualitative and Quantitative Performance for MSE-based Label-free ProteomicsJournal of Proteome Research, 2013
- Affinity Depletion of Plasma and Serum for Mass Spectrometry-Based Proteome Analysis2013
- Thioredoxin, a novel oxidative stress marker and cognitive performance in chronic and medicated schizophrenia versus healthy controlsSchizophrenia Research, 2013
- Potential biomarkers in psychiatry: focus on the cholesterol systemJournal of Cellular and Molecular Medicine, 2012
- Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patientsTranslational Psychiatry, 2012
- Characterization of the human serum depletome by label‐free shotgun proteomicsJournal of Separation Science, 2011
- Converging evidence of blood-based biomarkers for schizophreniaInternational Review of Neurobiology, 2011
- Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and futureSchizophrenia Research, 2010
- Impaired glucose tolerance in first‐episode drug‐naïve patients with schizophreniaDiabetic Medicine, 2007